Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

April 1, 2024

https://www.globenewswire.com/news-release/2024/04/01/2855095/0/en/Ocuphire-Announces-the-U-S-Commercial-Launch-of-RYZUMVl-Phentolamine-Ophthalmic-Solution-0-75-by-its-Partner-Viatris.html

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ:VTRS).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.